| Num | PTM | Disease | Cell Type | Type | PTM Site | PMID |
|---|
| 1 | Phosphorylation | B-chronic lymphocytic leukemia | | A | | 23866081 |
[Reference]: CLL cells did not express EGFR and nonspecific staining with anti-phospho-EGFR antibodies was not observed |
|
| 2 | Phosphorylation | Thyroid cancer/carcinoma | | D | | 16822827 |
[Reference]: EGFR expression and phosphorylation in the thyroid carcinoma cell lines and tissue specimens were present but not stronger than in noncancerous thyroid tissue. |
|
| 3 | Phosphorylation | Lung adenocarcinoma | | P | | 23866081 |
[Reference]: Constitutive phosphorylation of EGFR at Y-845 in Calu3 and H1975 cell lines, and at Y-992 was seen in Calu3, H1975, and A549 cell lines |
|
| 4 | Phosphorylation | Epidermoid carcinoma | cell line | P | | 23499740 |
[Reference]: he results indicated that hIgG38 binding to L1 and hIgG45 binding to C2 substantially suppressed the EGF-induced phosphorylation of EGFR, resulting in the growth inhibition of A431 cancer cells |
|
| 5 | Phosphorylation | Thyroid cancer/carcinoma | | P | | 11299771 |
[Reference]: We have previously reported that apigenin inhibits the growth of thyroid cancer cells by attenuating epidermal growth factor receptor (EGF-R) tyrosine phosphorylation and phosphorylation of ERK mitogen-activated protein (MAP) kinase. |
|
| 6 | Phosphorylation | Ovarian cancer/carcinoma | | U | | 22952709 |
[Reference]: PEITC treatment caused significant down regulation of constitutive protein levels as well as phosphorylation of EGFR at Tyr1068 in various ovarian cancer cells |
|
| 7 | Phosphorylation | Colon cancer/carcinoma | | U | | 24665413 |
[Reference]: phosphorylation of Threonine 192 in Claudin-3 leads to disruption of TJs in an ovarian cancer cell line24 and increased phosphorylation of its C-terminal tyrosines was found in EGFR and c-MET positive colon cancer cells |
|
| 8 | Phosphorylation | Head and neck squamous cell carcinoma | | U | | 23799848 |
[Reference]: Ron+HNSCC also had significantly higher EGFR expression and correlated strongly with phosphorylated EGFR (pEGFR) |
|
| 9 | Phosphorylation | Glioma/Adult gliomas | | U | | 24403856 |
[Reference]: The deltaEGFR-expressing U87 xenografts showed a high level of EGFR Y1173 phosphorylation compared to the low level seen in control U87 tumors. These results are consistent with in vitro experiments using these cell lines, which demonstrate high levels of constitutive EGFR Y1173 phosphorylation and low but EGF-inducible Y1173 phosphorylation of the endogenous, wild-type receptor |
|
| 10 | Phosphorylation | Glioblastoma | | C | | 24346432 |
[Reference]: EGFR phosphorylation was increased only in LCM-enriched tumor specimens carrying EGFR mutations. Phosphorylated and total PTEN, which is highly expressed in normal brain, was reduced only in LCM-enriched tumor specimens with either PTEN mutation or loss in PTEN copy number, with no differences observed in non-microdissected samples. |
|
| 11 | Serine Phosphorylation | Esophageal squamous cell carcinoma | | N | S768 | 16357520 |
[Reference]: As demonstrated by in vitro proliferation assay, this mutation sensitized Kyse450 cells to gefitinib. The observation of down regulation of the phosphorylated pAKT indicated gefitinib induced Kyse450 cells apoptosis via inhibition of EGFR activity |
|
| 12 | Serine Phosphorylation | Non-small cell lung cancer/carcinoma | cell line | N | S768 | 17653080 |
[Reference]: S768I and L861Q mutants were less sensitive to Src suppression than others. Mutation at tyrosine 869 (845) residue, an Src phosphorylation site, decreased the phosphorylation levels of wild-type EGFR and other mutants, but not that of S768I and L861Q mutants, suggesting that S768I and L861Q mutants became Src independent for their activation and biological functions. |
|
| 13 | Threonine Phosphorylation | Non-small cell lung cancer/carcinoma | | N | T790 | 18199554 |
[Reference]: Of note, EGFR T790M, a receptor variant found in patients with gefitinib-resistant NSCLC, was also resistant to lapatinib-mediated inhibition of receptor autophosphorylation. |
|
| 14 | Tyrosine Phosphorylation | Lung adenocarcinoma | | P | Y845 | 23866081 |
[Reference]: Constitutive phosphorylation of EGFR at Y-845 in Calu3 and H1975 cell lines, and at Y-992 was seen in Calu3, H1975, and A549 cell lines |
|
| 15 | Tyrosine Phosphorylation | Breast cancer/tumor/carcinoma | | P | Y845 | 22179831; 23066441 |
[Reference]: EGFR Tyrosine 845 Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer Cells Require Activation of p38 MAPK |
|
| 16 | Tyrosine Phosphorylation | Liver cancer | cell line | P | Y845 | 23220047 |
[Reference]: The COOH-terminus of TM4SF5 in hepatoma cell lines regulates c-Src to form invasive protrusions via EGFR Tyr845 phosphorylation |
|
| 17 | Tyrosine Phosphorylation | Non-small cell lung cancer/carcinoma | | U | Y869 | 17653080; 16505275 |
[Reference]: Mutation at tyrosine 869 (845) residue, an Src phosphorylation site, decreased the phosphorylation levels of wild-type EGFR and other mutants, but not that of S768I and L861Q mutants, suggesting that S768I and L861Q mutants became Src independent for their activation and biological functions. |
|
| 18 | Tyrosine Phosphorylation | Gastric cancer | AGS cell line | P | Y992 | 23613900 |
[Reference]: PKG II inhibited EGF-induced migration activity and blocked EGF-initiated signal transduction of PLC1 and MAPK/ERK-mediated pathways through preventing EGF-induced Tyr 992 and Tyr 1068 phosphorylation of EGFR. PKG II bound with EGFR and caused threonine phosphorylation of it |
|
| 19 | Tyrosine Phosphorylation | Non-small cell lung cancer/carcinoma | | U | Y1016 | 19002495 |
[Reference]: Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. |
|
| 20 | Tyrosine Phosphorylation | Breast cancer/tumor/carcinoma | cell line | C | Y1045 | 16969069 |
[Reference]: These results suggest that hypophosphorylation of tyrosine residue 1045 is likely to be the cause for EGFRvIII escape from c-Cbl-induced ubiquitination and degradation, enhancing EGFRvIII?? ability to increase proliferation in breast cancer cells |
|
| 21 | Serine Phosphorylation | Non-small cell lung cancer/carcinoma | tumor tissue | U | S1046 | 23520446 |
[Reference]: The expression of pEGFR-Ser1046 and AURKA was significantly higher in tumors than in the adjacent normal tissue (p = 0.001) of 25 NSCLC patients |
|
| 22 | Tyrosine Phosphorylation | Non-small cell lung cancer/carcinoma | cell line | P | Y1068 | 22901364 |
[Reference]: Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR |
|
| 23 | Tyrosine Phosphorylation | Gastric cancer | AGS cell line | P | Y1068 | 23613900 |
[Reference]: PKG II inhibited EGF-induced migration activity and blocked EGF-initiated signal transduction of PLC1 and MAPK/ERK-mediated pathways through preventing EGF-induced Tyr 992 and Tyr 1068 phosphorylation of EGFR. PKG II bound with EGFR and caused threonine phosphorylation of it |
|
| 24 | Tyrosine Phosphorylation | Tonsillar cancer | tumor tissue | P | Y1068 | 23564800 |
[Reference]: Since pEGFR Tyr1068 and 1148 are correlated to absence of HPV but not to clinical outcome, these may not be optimal prognostic markers for clinical outcome in patients with TSCC |
|
| 25 | Tyrosine Phosphorylation | Prostate cancer/carcinoma/adenocarcinoma | tumor tissue | U | Y1068 | 22307624 |
[Reference]: Tyrosine Phosphorylation Is Increased in Clinical Castration-Resistant Prostate Cancer Samples |
|
| 26 | Tyrosine Phosphorylation | Non-small cell lung cancer/carcinoma | | D | Y1069 | 18687633 |
[Reference]: Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. |
|
| 27 | Tyrosine Phosphorylation | Breast cancer/tumor/carcinoma | | U | Y1086 | 22222162 |
[Reference]: We found that there was an increase in phosphorylation of pY1086 EGFR after 18 h EtOH treatment in CYP2E1 overexpressing cells. These studies support a hypothesis that EtOH might increase human mammary cell activation, via an EGFR-dependent signaling mechanism associated with oxidative stress |
|
| 28 | Tyrosine Phosphorylation | Non-small cell lung cancer/carcinoma | | U | Y1092 | 17653080; 18687633; 28724430 |
[Reference]: EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer. |
|
| 29 | Tyrosine Phosphorylation | Tonsillar cancer | tumor tissue | P | Y1148 | 23564800 |
[Reference]: Since pEGFR Tyr1068 and 1148 are correlated to absence of HPV but not to clinical outcome, these may not be optimal prognostic markers for clinical outcome in patients with TSCC |
|
| 30 | Serine Phosphorylation | Lung cancer/carcinoma | | P | S1166 | 22703031 |
[Reference]: EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth |
|
| 31 | Tyrosine Phosphorylation | Non-small cell lung cancer/carcinoma | | U | Y1172 | 18687633 |
[Reference]: Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. |
|
| 32 | Arginine Methylation | Breast cancer/tumor/carcinoma | MCF7 cell line | A | R1175 | 21258366 |
[Reference]: Using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assays, we observed that MCF7-EGFR (R1175K) cells grew more quickly than MCF7-EGFR (WT) cell |
|
| 33 | Tyrosine Phosphorylation | Non-small cell lung cancer/carcinoma | | U | Y1197 | 19002495 |
[Reference]: Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. |
|